Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX4PWV)

Drug Name

ASP1951 Drug Info

Synonyms

PTZ-522

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Activation-inducible TNFR family receptor (TNFRSF18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
INCAGN01876	DMNUXKA	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
INCAGN1876	DM8XN4A	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
TRX-518	DMQS5DY	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
MK-4166	DML5V76	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
REGN6569	DM0ZMNI	Squamous head and neck cell carcinom	2D60.0	Phase 1	[6]
AMG 228	DMLQJ5P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
TRX518	DM9IDUH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Activation-inducible TNFR family receptor (TNFRSF18)	TTG6LA7	TNR18_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03799003) A Study of ASP1951 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Agenus.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5.
5	Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5.
6	Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
7	Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J Immunother Cancer. 2018 Sep 25;6(1):93.
8	Clinical pipeline report, company report or official report of Leap Therapeutics.